Patent US4434230A successfully refreshed from Google Patents.
US4434230A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Human nonsecretory plasmacytoid cell line
Assignee: Research Corp
•
Filing: 1981-08-12
•
Granted: 1984-02-28
•
Expires: 2001-08-12
Abstract
Abstract A human non-secretory plasmacytoid continuous cell line, established for five years in more than 150 passages, is karyotypically normal, easily grown and has the characteristic features of a plasmablast excepting for its secretory defect, and can be used for the preparation of human-human hybridomas with human B-lymphocytes and separation of the resulting hybridomas from the plasmacytoma cell line by growth in CO 2 -containing media, or by fluorescence activated cell sorting, or both.
Inventors
- 👤 Roy E. Ritts, Jr.
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-03 13:21
CPC Classifications
C; C12; C12N; C12N5/00; C12N5/10; C12N5/12; C12N5/16; C12N5/163; C07; C07K; C07K16/00; C07K16/08; C07K16/081; C07K16/085; C12N2500/00; C12N2500/02; Y; Y10; Y10S; Y10S435/00; Y10S435/8215; Y10S435/948
Claims Analysis
Total Claims: 7
Claim 1
Independent Claim
23 words
A biologically pure cell culture comprising a continuous human, non-antibody-secreting, plasmacytoid cell line having ATCC deposit number CRL-8083 and clones or subclones thereof.
Claim 2
Dependent Claim
23 words
A biologically pure cell culture comprising a continuous human, non-antibody-secreting, plasmacytoid cell line having ATCC deposit number CRL-8083 and clones or subclones thereof.
Claim 3
Dependent Claim
44 words
A method of producing human-human hybridomas which comprises: fusing an antibody producing human B-lymphocyte, with the non-secretory human plasmacytoma of claim 1 to thereby form an antibody-producing hybridoma; selecting for said hybridoma in a media containing from about 9% to about 11% carbon dioxide.
Claim 4
Dependent Claim
65 words
A method of producing human-human hybridomas which comprises: fusing an antibody producing human B-lymphocyte with the non-secretory human plasmacytoma of claim 1 to form an antibody-producing hybridoma; mixing the resulting reaction mixture with fluorescent-labeled antibodies thereby allowing said fluorescent labeled antibodies to bind to said hybridoma; and separating said hybridomas complexed with said fluorescent antibodies from said non-secretory human plasmacytoma by fluorescence activated cell sorting.
Claim 5
Independent Claim
16 words
The method of any of claims 2 or 3 wherein said hybridoma is cultured in vitro.
Claim 6
Dependent Claim
50 words
The method of claim 2 which also comprises admixing the reaction mixture containing the fused hybridomas and the non-secretory plasmacytoma with fluorescent-labeled antibodies thereby allowing said antibodies to bind to said hybridomas and; separating said non-secretory human plasmacytoma from said hybridomas carrying said fluorescent antibodies, by fluorescensce activated cell sorting.
Claim 7
Dependent Claim
32 words
The method of claim 5 wherein the separation by fluorescence activated cell sorting is carried out prior to the selection in media containing from about 9% to about 11% CO 2 .
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-02-27 | 1987-08-29 | 1988-02-28 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-02-27 | 1991-08-29 | 1992-02-28 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-02-27 | 1995-08-29 | 1996-02-28 | $7700.00 | Window Closed / Lapsed |